Page 16 - B Cell News Today

SHREVEPORT, La. — In terms of fighting COVID-19, whether through natural infection or vaccination, the part of the immune system most often mentioned are antibodies.

In a new study, researchers elucidated the factors driving adaptive evolution in chronic SARS-CoV-2 infections.

WEDNESDAY, March 2, 2022 (HealthDay News) -- People whove had COVID-19 may have long-term immune protection against new variants of the virus, but researchers say vaccination remains the best safeguard

As Omicron wanes, so has tolerance for many efforts pushed to keep the pandemic in check for the past two years.

A recent study observed that peptide-based vaccination against SARS-CoV-2 failed to protect mice against COVID-19, albeit eliciting T cell responses.

Researchers emphasized the need to take on a holistic and unbiased approach to develop a universal vaccine for coronaviruses, including SARS-CoV-2, which is a biomedical priority during the ongoing COVID-19 pandemic.

SHREVEPORT, La. — New studies say that booster shots will continue to protect most people from severe COVID-19 illness and death for many months, possibly years.

Researchers characterized humoral and SARS-CoV-2 S-specific T cell responses in IBD patients who received two-dose mRNA-based COVID-19 vaccination series.

Scientists evaluated the incidence and severity of breakthrough SARS-CoV-2 infections among individuals with immune-mediated inflammatory diseases undergoing B cell depleting therapy.

A new study examined how the quantity and quality of antibody and memory B cell responses to SARS-CoV-2 change temporally and with the number of exposures to antigens.